MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside ...

Rectal discharge may appear in the toilet after pooping or on toilet paper without the urge to have a bowel movement. This ...

Sales of Travelan ® increased 48% to AUD $0.456 million in the September 2024 Quarter compared to AUD $0.309 million in the ...

Immuron’s financial position remains solid, giving it a long cash runway for its ongoing clinical trials. including the Phase 2 trial of Travelan® and the development of IMM-529, without immediate ...

The details of the trial are available at clinicaltrials.gov/study/NCT06122870 . The trial was funded by the NMRC. Immuron’s ...

with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with ...